Rockville, MD, May 6, 2003 – Rexahn Corp. announced today that it has signed a Collaborative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health. The agreement provides for NCI and Rexahn to investigate the effect of a family of protein kinases on the growth and proliferation of mammalian cells. This CRADA is the first step in the R&D process of identifying new drug candidates to treat cancer.
Under the CRADA, scientists from Rexahn Corp. and NCI will work together to discover the anti-mitotic and anti-proliferative compounds from a chemical library synthesized by Rexahn using the NCI-developed kinase expression systems.
Chang Ahn, PhD, Chairman and CEO of Rexahn, said, “The CRADA with the NCI is an important milestone for Rexahn Corp. In addition to providing the company access to leading edge scientific systems and world renowned scientists, this agreement is also a validation of Rexahn’s science, intellectual property, know-how, and performance. We welcome the collaboration with NCI and look forward to working with them in this early process of discovery for novel anticancer products.”